Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16199438 | 0.87 | MEN1 (0.54) | RORCKAT6APKMKDM4EMAPT | |
| SCHEMBL656043 | 0.83 | ALDH1A1 (0.60) | KAT6ACA1CA2MAPT | |
| SCHEMBL29478358 | 0.83 | ALDH1A1 (0.60) | KAT6ACA1CA2MAPT | |
| SCHEMBL13623011 | 0.82 | ALOX5 (0.67) | HTR6PKMCA1CA2MAPT | |
| SCHEMBL1074934 | 0.81 | POLB (0.70) | POLBHTR6PKMCA1CA2 | |
| SCHEMBL13623016 | 0.81 | ALDH1A1 (0.48) | RORCKAT6ACA1CA2 | |
| SCHEMBL18391079 | 0.79 | ALDH1A1 (0.54) | KAT6AKDM4ECA1MAPTKMT2A | |
| SCHEMBL15647660 | 0.79 | MMP1 (0.57) | RORCKAT6AKDM4ECA2MAPT | |
| SCHEMBL29029431 | 0.79 | HDAC3 (0.56) | RORCKAT6ACA1CA2MAPT | |
| SCHEMBL7151558 | 0.79 | ALOX5 (0.66) | POLBKAT6APKMCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | POLB 2346/4885HTR6 4707/4885RORC 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.